

DAFTAR PUSTAKA

1. Ghallab DS, Shawky E, Metwally AM, Celik I, Ibrahim RS, Mohyeldin MM. Integrated: In silico - In vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat. *RSC Adv.* 2022;12(5):2843–72.
2. Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. *Br J Clin Pharmacol.* 2008;65(3):355–63.
3. Kumar Bandaru R, Rout SR, Kenguva G, Gorain B, Alhakamy NA, Kesharwani P, et al. Recent Advances in Pharmaceutical Cocrystals: From Bench to Market. *Front Pharmacol.* 2021;12(November):1–16.
4. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm.* 2012;2012(100 mL):1–10.
5. Deshpande MN, Dessai SS, Dighe P. Solid Dispersion Systems of Poorly Water Soluble Drug Febuxostat: Preparation, Characterization and Optimization. *Indian Drugs.* 2023;60(10):40–7.
6. Jagia M, Kale DP, Bansal AK, Patel S. Novel Co-crystals and Eutectics of Febuxostat: Characterization, Mechanism of Formation, and Improved Dissolution. *AAPS PharmSciTech.* 2022;23(1):1–17.
7. Ungur DT, Santiso-Quinones G, Pop MM, Tamas TL, Guguta C, Stam D, et al. Febuxostat-p-Toluenesulfonic Acid Multi-Component Crystal: Characterization, Crystal Growth and Elucidation of the Salt/Co-Crystal Nature. *Crystals.* 2023;13(5).
8. Pandi P, Bulusu R, Kommineni N, Khan W, Singh M. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. *Int J Pharm.* 2020;586:1–28.
9. Yu D, Xue Z, Mu T. Eutectics: Formation, properties, and applications. *Chem Soc Rev.* 2021;50(15):8596–638.
10. Berry DJ, Steed JW. Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design. *Adv Drug Deliv Rev.* 2017;117:3–24.
11. Triyana R, Nurhabibah N, Sopyan I. Artikel Review : Kokristal Ibuprofen dengan Berbagai Koformer, Virtual Screening Tools. *Maj Farmasetika.* 2020;6(1):23.
12. Ragnar M, Lindgren CT. Journal of Wood Chemistry and pK a -Values of Guaiacyl and Syringyl Phenols Related to Lignin. 2008;(March 2013):277–305.
13. Srinivasulu C, Ramgopal M, Ramanjaneyulu G, Anuradha CM, Suresh Kumar C. Syringic acid (SA) – A Review of Its Occurrence, Biosynthesis,

- Pharmacological and Industrial Importance. *Biomed Pharmacother.* 2018;108(September):547–57.
14. Cvetkovski A, Ferretti V, Bertolasi V. New pharmaceutical salts containing pyridoxine. *Acta Crystallogr Sect C Struct Chem.* 2017;73(12):1064–70.
 15. Yadav B, Balasubramanian S, Chavan RB, Thipparaboina R, Naidu VGM, Shastri NR. Hepatoprotective Cocrystals and Salts of Riluzole: Prediction, Synthesis, Solid State Characterization, and Evaluation. *Cryst Growth Des.* 2018;18(2):1047–61.
 16. Ying P, Yu J, Su W. Liquid-Assisted Grinding Mechanochemistry in the Synthesis of Pharmaceuticals. *Adv Synth Catal.* 2021;363(5):1246–71.
 17. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. *Acta Pharm Sin B.* 2021;11(8):2537–64.
 18. Pawar N, Saha A, Nandan N, Parambil J V. Solution cocrystallization: A scalable approach for cocrystal production. *Crystals.* 2021;11(3).
 19. Rodrigues M, Baptista B, Lopes JA, Sarraguça MC. Pharmaceutical cocrystallization techniques. Advances and challenges. *Int J Pharm.* 2018;547(1–2):404–20.
 20. Sultan M, Wu J, Haq IU, Imran M, Yang L, Wu JJ, et al. Recent Progress on Synthesis, Characterization, and Performance of Energetic Cocrystals: A Review. *Molecules.* 2022;27(15).
 21. Ministry of Health, Labour and Welfare (MHLW), 2021. *The Japanese Pharmacopoeia, 18th Edition.* Tokyo: Pharmaceuticals and Medical Devices Agency (PMDA).
 22. Kang Y, Gu J, Hu X. Syntheses, structure characterization and dissolution of two novel cocrystals of febuxostat. *J Mol Struct [Internet].* 2017;1130:480–6.
 23. National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 134018, Febuxostat.
 24. Robinson PC, Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. *Expert Opin Pharmacother [Internet].* 2018;19(11):1289–99.
 25. Kamel B, Graham GG, Williams KM, Pile KD, Day RO. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. *Clin Pharmacokinet.* 2017;56(5):459–75.
 26. National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 10742, Syringic acid. accessed on 2024 October 2. from <https://pubchem.ncbi.nlm.nih.gov/compound/Syringic-acid>
 27. Shimsa S, Mondal S, Mini S. Syringic Acid: A Promising Phenolic Phytochemical with Extensive Therapeutic Applications. *R&D Funct Food Prod.* 2024;1(5):1–14.

28. Ogut E, Armagan K, Gül Z. The role of syringic acid as a neuroprotective agent for neurodegenerative disorders and future expectations. *Metab Brain Dis.* 2022;37(4):859–80.
29. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Sci Pharm.* 2020;88.
30. Huang S, Xu J, Peng Y, Guo M, Cai T. Facile Tuning of the Photoluminescence and Dissolution Properties of Phloretin through Cocrystallization. *Cryst Growth Des.* 2019;19(12):6837–44.
31. Nurismi E, Rosaini H, Octavia D. Review : Effect of Different Methods on the Multicomponents Crystal Formation from Medicinal Natural Ingredient Compounds. 2021;6:32–9.
32. Kumar S, Nanda A. Pharmaceutical cocrystals: An overview. *Indian J Pharm Sci.* 2017;79(6):858–71.
33. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev.* 2017;117:25–46.
34. Samineni R, Chimakurthy J, Konidala S. Emerging Role of Biopharmaceutical Classification and Biopharmaceutical Drug Disposition System in Dosage form Development: A Systematic Review. *Turkish J Pharm Sci.* 2022;19(6):706–13.
35. Sedghiniya S, Soleimannejad J, Janczak J. The salt–cocrystal spectrum in salicylic acid–adenine: the influence of crystal structure on proton-transfer balance. *Acta Crystallogr Sect C Struct Chem.* 2019;75(4):412–21.
36. Gupta D, Bhatia D, Dave V, Sutariya V, Gupta SV. Salts of therapeutic agents: Chemical, physicochemical, and biological considerations. *Molecules.* 2018;23(7).
37. Vemuri VD, Lankalapalli S. Insight into concept and progress on pharmaceutical co-crystals: An overview. *Indian J Pharm Educ Res.* 2019;53(4):s522–38.
38. Wang Y, Wang L, Zhang F, Wang N, Gao Y, Xiao Y, et al. Structure Analysis and Insight into Hydrogen Bond and van der Waals Interactions of Etoricoxib Cocrystals and Cocrystal Solvate. *J Mol Struct.* 2022;1258:132665.
39. Singh M, Barua H, Jyothi VGSS, Dhondale MR, Nambiar AG, Agrawal AK, et al. Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems. *Pharmaceutics.* 2023;15(4).
40. Rachmaniar R, Tristiyanti D, Sari DY. [Review] Pengaruh Koformer Nikotinamid Dan Metode Pembentukan Kokristal Terhadap Kelarutan Zat Aktif Tidak Larut Air. *J Sains dan Teknol Farm Indones.* 2020;9(1).
41. Wathoni N, Sari WA, Elamin KM, Mohammed AFA, Suharyani I. A Review

- of Coformer Utilization in Multicomponent Crystal Formation. *Molecules*. 2022;27(24).
42. Thayyil AR, Juturu T, Nayak S, Kamath S. Pharmaceutical Co-crystallization: Regulatory aspects, design, characterization, and applications. *Adv Pharm Bull* [Internet]. 2020;10(2):203–12.
 43. Lange L, Heisel S, Sadowski G. Predicting the solubility of pharmaceutical cocrystals in solvent/anti-solvent mixtures. *Molecules*. 2016;21(5).
 44. Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ. Anti-solvent co-crystallization of carbamazepine and saccharin. *Int J Pharm* [Internet]. 2013;450(1–2):311–22.
 45. Grossjohann C, Serrano DR, Paluch KJ, O’Connell P, Vella-Zarb L, Manesiotis P, et al. Polymorphism in Sulfadimidine/4-Aminosalicylic Acid Cocrystals: Solid-State Characterization and Physicochemical Properties. *J Pharm Sci*. 2015;104(4):1385–98.
 46. Karagianni A, Malamataris M, Kachrimanis K. Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. *Pharmaceutics*. 2018;10(1):1–30.
 47. Buddhadev SS, Garala KC. Pharmaceutical Cocrystals—A Review. 2021;14.
 48. Patil H, Tiwari R V., Repka MA. Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation. *AAPS PharmSciTech*. 2016;17(1):20–42.
 49. Nugrahani I, Jessica MA. Amino acids as the potential co-former for co-crystal development: A review. *Molecules*. 2021;26(11).
 50. Marquez J, Novikov E, Rigin S, Fonari MS, Castañeda R, Kornilova T, et al. Exploiting Supramolecular Synthons in Cocrystals of Two Racetams with 4-Hydroxybenzoic Acid and 4-Hydroxybenzamide Coformers. *Chem*. 2023;5(2).
 51. Chettri A, Subba A, Singh GP, Bag PP. Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy. *J Pharm Pharmacol*. 2024;76(1):1–12.
 52. Patel VP, Patel AP, Shah A. Optimization of Amorphous Solid Dispersion Techniques to Enhance Solubility of Febuxostat. *Folia Med (Plovdiv)*. 2021;63(4):557–68.
 53. Gonon M. Case Studies in the X-ray Diffraction of Ceramics. In: Pomeroy M, editor. *Encyclopedia of Materials: Technical Ceramics and Glasses* Oxford: Elsevier; 2021. p. 560–77.
 54. Martin FASDP. European Patent Application. EP Pat 0879946A2 [Internet]. 1998;1(19):1–14.
 55. Chauhan A. Powder XRD Technique and its Applications in Science and

- Technology. *J Anal Bioanal Tech*. 2014;5(6).
56. Tripura Sundari P, Lad K. Physico-chemical characterization and in vitro evaluation of biopharmaceutics classification system class II drug febuxostat. *Asian J Pharm*. 2016;10(2):S162–9.
 57. Ramadhan SA, Musfiroh I. Review Artikel: Verifikasi Metode Analisis Obat. *Farmaka*. 2021;19:87–92.
 58. Abdullah A, Sangkal A, Ismail R. UV-Vis Spectrophotometric Method Validation of Cefixime in Phosphate Buffer. *J Ilmu Kefarmasian*. 2022;3(2):144–7.
 59. Sharma SK, Verma DS, Khan LU, Kumar S, Khan SB. Handbook of Materials Characterization. *Handb Mater Charact*. 2018;1–613.
 60. Davies TE, Li H, Bessette S, Gauvin R, Patience GS, Dummer NF. Experimental methods in chemical engineering: Scanning electron microscopy and X-ray ultra-microscopy—SEM and XuM. *Can J Chem Eng*. 2022;100(11):3145–59.
 61. Hattori Y, Haruna Y, Otsuka M. Dissolution process analysis using model-free Noyes-Whitney integral equation. *Colloids Surfaces B Biointerfaces*. 2013;102:227–31.
 62. Shargel L, Yu ABC. *Applied Biopharmaceutics & Pharmacokinetics*. In: 7th ed. New York, NY: McGraw-Hill Education; 2016
 63. Profile SEE. A Review : HPLC Method Development and Validation ISSN-2231-5012 Review Article A Review : HPLC Method Development and Validation. 2016.
 64. Susanti M, Dachriyanus. *Kromatografi Cair Kinerja Tinggi*. Padang: Carano Pustaka Universitas Andalas; 2017
 65. Pratiwi RA, Nandiyanto ABD. How to Read and Interpret UV-VIS Spectrophotometric Results in Determining the Structure of Chemical Compounds. *Indones J Educ Res Technol*. 2022;2(1):1–20.
 66. Aulia SS, Sopyan I, Muchtaridi. Penetapan Kadar Simvastatin Menggunakan Kromatografi Cair Kinerja Tinggi (KCKT). *Farmaka*. 2016;14(4):70–8.
 67. Stauffer MT. Introductory Chapter: The Many Faces of Calibration and Validation in Analytical Methodology in the Present Day. In: Stauffer MT, editor. *Calibration and Validation of Analytical Methods*. Rijeka: IntechOpen; 2018
 68. Garbacz P, Wesolowski M. DSC, FTIR and raman spectroscopy coupled with multivariate analysis in a study of co-crystals of pharmaceutical interest. *Molecules*. 2018;23(9).
 69. Fatimah S, Ragadhita R, Al Husaeni DF, Nandiyanto ABD. How to Calculate Crystallite Size from X-Ray Diffraction (XRD) using Scherrer Method. *ASEAN J Sci Eng*. 2022;2(1):65–76.

70. Mannava MKC, Gunnam A, Lodagekar A, Shastri NR, Nangia AK, Solomon KA. Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation. *CrystEngComm*. 2021;23(1):227–37.
71. Segneanu AE, Orbeci C, Lazau C, Sfirloaga P, Vlazan P, Bandas C, et al. Methods Validation. *Web Sci*. 2013;29.
72. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. *J Control Release*. 2001;73(2–3):121–36.
73. Yang B, Wei C, Qian F, Li S. Surface Wettability Modulated by Surfactant and Its Effects on the Drug Release and Absorption of Fenofibrate Solid Dispersions. *AAPS PharmSciTech*. 2019;20(6).
74. Sohn JS, Choi JS. Development and evaluation of febuxostat solid dispersion through screening method. *Saudi Pharm J*. 2023;31(9):101724.
75. Rahman SMH, Telny TC, Ravi TK, Kuppusamy S. Role of surfactant and pH in dissolution of curcumin. *Indian J Pharm Sci*. 2009;71(2):139–42.

